PharmiNews

The Directory of Pharma Companies and News

Regeneron

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, atopic dermatitis and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, pain, cancer and infectious diseases.
Category: Biotech
Category: Biotech

Regeneron News

DateNews
2017-01-13Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals...
2017-01-09Sanofi and Regeneron Provide Update on Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
2017-01-06Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab)...
2017-01-04Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
2016-12-22Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
2016-12-22Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health Sys...
2016-12-22Regeneron Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference
2016-12-08Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the E...
2016-11-21Regeneron CEO Leonard Schleifer and CSO George Yancopoulos Named EY 2016 National Life Sciences Entrepreneurs Of The Yea...
2016-11-17Regeneron and Sanofi Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following In...
2016-11-16Regeneron and Sanofi Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheu...
2016-09-26Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
2016-09-20Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody...
2016-09-12Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
2016-08-29Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Unde...
2016-08-22Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
2016-08-04Regeneron Reports Second Quarter 2016 Financial and Operating Results
2016-08-02Regeneron and Adicet Bio Announce Strategic Collaboration to Discover and Develop Next-Generation Engineered Immune Cell...
2016-07-13Regeneron Announces 2016 Winners of the Regeneron Prize for Creative Innovation
2016-07-12Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psycholog...
2016-07-08Regeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4...
2016-07-05Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
2016-06-06Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS ...
2016-05-31Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous F...
2016-05-26Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search
2016-05-26Words of Support from Public Figures on Regeneron STS Sponsorship
2016-05-25Regeneron Announces Important US Prescribing Information Clarification for EYLEA® (afl...
2016-05-11Regeneron and Sanofi Genzyme to Present Additional Data from Pivotal Phase 2b Dupilumab Study in Adults with Uncontrolle...
2016-05-05Regeneron Reports First Quarter 2016 Financial and Operating Results
2016-05-02Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
2016-04-29Regeneron Announces Upcoming 2016 Investor Conference Presentations
2016-04-15Regeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 20...
2016-04-13Regeneron Hires Sally A. Paull as Senior Vice President, Human Resources
2016-04-11Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
2016-04-05Regeneron and MedImmune Enter into Licensing Agreement for the Development of Antibody Drug Conjugates to Treat Cancer
2016-04-01Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Mode...
2016-03-30Regeneron and Sanofi to Present Phase 3 Praluent® (alirocumab) Injection Clinical Tria...
2016-03-24Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
2016-03-23Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing ...
2016-03-16Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocum...
2016-03-11Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Ad...
2016-03-04Regeneron and Sanofi Announce Humana Provides Exclusive or Preferred Access to Praluent® (alirocumab) Injection on their...
2016-03-02Regeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary A...
2016-03-01Regeneron Hires David Weinreich, M.D., M.B.A., as Senior Vice President, Late Stage Clinical Development and Medical Aff...
2016-02-10Regeneron Joins Human Vaccines Project to Improve Global Disease Prevention and Treatment
2016-02-09Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
2016-02-02Regeneron Announces Upcoming 2016 Investor Conference Presentation
2016-02-02Regeneron and Sanofi Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical A...
2016-01-26Regeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host Conference Call and Webca...
2016-01-08Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA
2016-01-07Regeneron Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference
2015-12-27Regeneron Mourns Passing of Dr. Alfred G. Gilman, Board Member and Nobel Laureate
2015-12-11Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access
2015-11-24Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled
2015-11-12Regeneron Celebrates Patient Innovation and Growth in New York State
2015-11-10Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
2015-11-08Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual ...
2015-11-05New Survey of U.S. Adults with Diabetes Reveals Less than Half Understand Their Risk for Vision Loss
2015-11-05Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific ...
2015-11-05Regeneron and Sanofi to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific ...
2015-11-04Regeneron Reports Third Quarter 2015 Financial and Operating Results
2015-10-30Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to My...
2015-10-29Regeneron Named Among Top Two Global Biopharmaceutical Employers by Science Magazine for Fifth Year in a Row
2015-10-23Regeneron Announces Presentation at the 24th Annual Credit Suisse Healthcare Conference
2015-10-19Regeneron Announces an Additional $350 Million Investment and 200 New Jobs in Limerick by End-2017
2015-10-08Regeneron to Report Third Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on November ...
2015-10-08Regeneron and Sanofi Announce Publication of Positive Phase 2b Dupilumab Data in The Lancet
2015-10-01Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
2015-09-28Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the Europe...
2015-09-24Regeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement
2015-09-21Regeneron Announces Agreement with BARDA for the Development of New Antibody Treatment for Ebola
2015-09-10Regeneron Hires Maya Bermingham as Executive Director, Public Policy
2015-09-02Regeneron Discovery on Cause of Rare Genetic Bone Disease Detailed in Science Translational Medicine Publicatio...
2015-09-01Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015
2015-08-04Regeneron Reports Second Quarter 2015 Financial and Operating Results
2015-07-28Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration
2015-07-24Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hyperchol...
2015-07-24Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., f...
2015-07-09Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Trea...
2015-07-08Regeneron to Report Second Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on August 4...
2015-06-30New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol
2015-06-29Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of S...
2015-06-26EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
2015-06-25Regeneron Announces 2015 Winners of the Regeneron Prize for Creative Innovation
2015-06-09Trading in Regeneron Common Stock Halted
2015-06-09FDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with ...
2015-05-21Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid A...
2015-05-18Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Soci...
2015-05-07Regeneron Reports First Quarter 2015 Financial and Operating Results
2015-04-10Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 20...
2015-03-25EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic...
2015-03-15Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The N...
2015-02-26EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondar...
2015-02-18NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrate...
2015-02-18New Results from Cholesterol Counts Show Most Americans Polled Do Not Know Their Bad Cholesterol (LDL-C) Levels
2015-02-13Regeneron Announces Upcoming 2015 Investor Conference Presentations
2015-02-10Regeneron Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
2015-01-26Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review...
2015-01-23EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Seco...
2015-01-12Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by...
2015-01-09Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webca...
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.